InformedDNA announced today that it will collaborate with NIA Magellan, a division of Magellan Health, Inc. (NASDAQ: MGLN), to offer an evidence-based genetic benefits optimization program. InformedDNA's national network of independent board-certified genetics specialists provides expert clinical review services to ensure appropriate use of genetic testing and improve patient care, while at the same time delivering significant cost savings. NIA Magellan, a division of Magellan Health, Inc. offers a suite of specialty solutions to address many complex areas of healthcare.
With rapid growth in the number of new genetic tests being brought to market and the high rate of inappropriate ordering, this collaboration provides a critical solution by offering genetic testing guidance by independent genetics specialists to patients and physicians alike. This approach has been proven to deliver high-quality, cost-effective and clinically actionable genetic testing.
"As the premier genetic benefits management organization, deploying InformedDNA's genetics expertise within NIA Magellan's established technology infrastructure allows InformedDNA to continue our rapid growth with health plan customers of all sizes," stated InformedDNA chief executive officer David Nixon. "Personalized medicine will continue to be one of the most powerful trends in healthcare for years to come. Collaborating with NIA Magellan positions us to expand delivery of our highly successful patient- centric approach that improves care while optimizing costs," Nixon concluded.
InformedDNA empowers personalized healthcare by providing genetics expertise to health plans, decision support to providers and expert genetic counseling services to patients.
"Advances in genetic testing are at the forefront of personalized healthcare, enabling individuals to make informed choices about their healthcare," said Tina M. Blasi, chief executive officer of NIA Magellan. "With those advancements, however, we must also ensure we are diligently monitoring the clinical appropriateness of genetic testing and, most importantly, that we are providing the genetic counseling and information necessary for individuals to best understand the results and any subsequent care that may be needed. Collaborating with InformedDNA will provide our customers and their members with genetics expertise that, when coupled with NIA Magellan's existing infrastructure and clinical leadership, will help to improve care and avoid unnecessary and costly tests. I'm excited about offering this cutting-edge capability."
NIA Magellan's suite of specialty solutions includes diagnostic imaging management services, as well as programs that manage the evaluation and therapy associated with cardiology services, musculoskeletal management, radiation oncology, obstetrical ultrasounds and sleep management.
Study identifies a potential treatment for Sandhoff and Tay-Sachs diseases